References
- Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403–12
- Scully RE, Bonfiglio TA, Kurman RJ, et al. Uterine corpus. In: Histological typing of female genital tract tumours. World Health Organization International Histological Classification of Tumors. 2nd ed. New York: Springer-Verlag Berlin Heidelberg; 1994:13
- Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? Gynecol Oncol 2000;76:287–90
- Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstetr Gynecol 1999;182:525–9
- Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstetr Gynecol 2009;200:678.e1–e6
- Lacey JV, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788–92
- Ozdegirmenci O, Kayikcioglu F, Bozkurt U, et al. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest 2011;72:10–14
- Reed SD, Voigt LF Newton KM, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstetr Gynecol 2009;113:655–62
- Hubbs JL, Saig RM, Abaid LN, et al. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol 2013;121:1172–80
- Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 1991;56:1034–9